Posted by Michael Wonder on 16 Jan 2025
PHARMAC consulting on widening access to venetoclax, azacitidine and upadacitinib monohydrate
16 January 2025 - PHARMAC is asking for feedback on a proposal to widen access to three medicines for five health conditions from 1 May 2025.
The medicines and health conditions are:
- Venetoclax (Venclexta) in combination with azacitidine or cytarabine for acute myeloid leukaemia
- Azacitidine to be used with venetoclax for acute myeloid leukaemia
- Upadacitinib monohydrate (Rinvoq) for atopic dermatitis, ulcerative colitis, Crohn's disease and rheumatoid arthritis
